What is HC Wainwright's Forecast for CRVS FY2024 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of ($0.41) for the year. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

Several other equities analysts also recently commented on the company. Mizuho upgraded Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 22nd. Oppenheimer raised their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. StockNews.com lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH upped their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.38.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS traded up $0.20 during trading hours on Monday, reaching $6.03. The stock had a trading volume of 821,176 shares, compared to its average volume of 844,455. The stock has a market capitalization of $387.47 million, a PE ratio of -6.48 and a beta of 1.07. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The company's 50-day moving average is $7.62 and its two-hundred day moving average is $5.36.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Corvus Pharmaceuticals during the second quarter worth $44,000. Nwam LLC acquired a new stake in Corvus Pharmaceuticals during the 3rd quarter worth about $53,000. XTX Topco Ltd acquired a new stake in Corvus Pharmaceuticals during the 3rd quarter worth about $74,000. Virtu Financial LLC bought a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth about $83,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $89,000. Institutional investors own 46.64% of the company's stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.